aibio
Debt Financing ·
Armata Pharmaceuticals signs $10 million loan from largest holder Innoviva at 14.0%
The secured term loan matures on March 12, 2026. Armata also pushed back the maturity of three earlier Innoviva credit agreements to the same date.
INVA Innoviva, Inc.
Innoviva (INVA) news
Latest Innoviva news
We have not published a story on Innoviva yet. When there is news, it will appear here.
Innoviva annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $30.6 million | $13.7 million |
| Net income (loss) | $271.2 million | $23.4 million |
| Cash from operations | $196.9 million | $188.7 million |
| Cash and equivalents | $550.9 million | $305.0 million |
Questions about Innoviva
What is the ticker symbol of Innoviva?
Innoviva, Inc. trades under the ticker INVA on NASDAQ.
Where is Innoviva listed?
Innoviva, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:HVE; LS:A2AC9U; LSX:A2AC9U.
What is the SEC CIK of Innoviva?
The SEC Central Index Key (CIK) for Innoviva, Inc. is 1080014. Its filings are on SEC EDGAR.
How many shares does Innoviva have outstanding?
72,245,485 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05.
Which country or territory is Innoviva listed under?
Our directory records Innoviva, Inc. under United States.
What does Innoviva do?
Our directory classifies Innoviva, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Innoviva?
The ISIN recorded for Innoviva, Inc. is US45781M1018.
Does aibio.space cover Innoviva?
aibio.space lists Innoviva, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Innoviva incorporated?
SEC records list its state or country of incorporation as DE.
Is Innoviva profitable?
Innoviva, Inc. reported net income of $271.2 million for the fiscal year ended Dec 31, 2025, and generated $196.9 million of cash from operations, per its annual report to the SEC.
How much does Innoviva spend on research and development?
$30.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Innoviva have?
$570.4 million in cash at Jun 30, 2026, per its 10-Q.
What is Innoviva's market cap?
We do not publish live share prices. In its annual report, Innoviva, Inc. put the market value of shares held by non-affiliates (public float) at $1.26 billion as of Jun 30, 2025.
Is Innoviva a smaller reporting company?
SEC records list Innoviva, Inc.'s filer category as: Large accelerated filer.
Where is Innoviva headquartered?
SEC records list its business address as 1350 OLD BAYSHORE HIGHWAY, BURLINGAME, CA, 94010.
Investor discussion: Innoviva
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Stock chart
SEC filings and registration
- SEC name
- Innoviva, Inc.
- CIK
- 1080014
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- INVA (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- 1350 OLD BAYSHORE HIGHWAY, BURLINGAME, CA, 94010
- Phone
- 6502389600
- Shares outstanding
- 72,245,485 as of 2026-07-31 (10-Q filed 2026-08-05)
- Former names
- THERAVANCE INC; ADVANCED MEDICINE INC
Recent filings
Listing details
- Company
- Innoviva, Inc.
- Ticker
- INVA
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US45781M1018
- Other listed symbols
- GETTEX:HVE; LS:A2AC9U; LSX:A2AC9U
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction